Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia

Reuters11-19

<a href="https://laohu8.com/S/SLNO">Soleno Therapeutics</a> Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia

Soleno Therapeutics Inc. has announced the launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in adults and pediatric patients aged four years and older with Prader-Willi syndrome $(PWS)$. The company highlighted a defined U.S. market opportunity of over $5 billion and a target patient population of approximately 10,000 individuals. VYKAT XR is protected by multiple layers of granted and pending patents extending into the mid-2030s, and Soleno reported achieving profitability and positive cash flow in the third quarter of 2025. Clinical trial data presented showed sustained reductions in hyperphagia, as measured by HQ-CT total scores, over multiple years in open-label and controlled studies. The company also emphasized the significant burden PWS places on patients, caregivers, and healthcare systems, including higher rates of hospital stays and increased caregiver stress. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584954619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584954619","market":"nz","top_or_hot":-1,"title":"Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced the launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in adults and pediatric patients aged four years and older with Prader-Willi syndrome <a href=\"https://laohu8.com/S/PWS\">$(PWS)$</a>. The company highlighted a defined U.S. market opportunity of over $5 billion and a target patient population of approximately 10,000 individuals. VYKAT XR is protected by multiple layers of granted and pending patents extending into the mid-2030s, and Soleno reported achieving profitability and positive cash flow in the third quarter of 2025. Clinical trial data presented showed sustained reductions in hyperphagia, as measured by HQ-CT total scores, over multiple years in open-label and controlled studies. The company also emphasized the significant burden PWS places on patients, caregivers, and healthcare systems, including higher rates of hospital stays and increased caregiver stress. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 00:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced the launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in adults and pediatric patients aged four years and older with Prader-Willi syndrome <a href=\"https://laohu8.com/S/PWS\">$(PWS)$</a>. The company highlighted a defined U.S. market opportunity of over $5 billion and a target patient population of approximately 10,000 individuals. VYKAT XR is protected by multiple layers of granted and pending patents extending into the mid-2030s, and Soleno reported achieving profitability and positive cash flow in the third quarter of 2025. Clinical trial data presented showed sustained reductions in hyperphagia, as measured by HQ-CT total scores, over multiple years in open-label and controlled studies. The company also emphasized the significant burden PWS places on patients, caregivers, and healthcare systems, including higher rates of hospital stays and increased caregiver stress. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL1H4phG:1","article_id":"2584954619","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584954619","pubTimestamp":1763484412,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Soleno Therapeutics Inc. has announced the launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in adults and pediatric patients aged four years and older with Prader-Willi syndrome . The company highlighted a defined U.S. market opportunity of over $5 billion and a target patient population of approximately 10,000 individuals. VYKAT XR is protected by multiple layers of granted and pending patents extending into the mid-2030s, and Soleno reported achieving profitability and positive cash flow in the third quarter of 2025. Clinical trial data presented showed sustained reductions in hyperphagia, as measured by HQ-CT total scores, over multiple years in open-label and controlled studies. The company also emphasized the significant burden PWS places on patients, caregivers, and healthcare systems, including higher rates of hospital stays and increased caregiver stress. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLNO":"Soleno Therapeutics"},"translate_title":"Soleno Therapeutics发布企业演示文稿，重点介绍针对Prader-Willi综合征食欲不振的VYKAT XR的推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLNO":0.9},"content_text":"Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia\n    \n\n        Soleno Therapeutics Inc. has announced the launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in adults and pediatric patients aged four years and older with Prader-Willi syndrome $(PWS)$. The company highlighted a defined U.S. market opportunity of over $5 billion and a target patient population of approximately 10,000 individuals. VYKAT XR is protected by multiple layers of granted and pending patents extending into the mid-2030s, and Soleno reported achieving profitability and positive cash flow in the third quarter of 2025. Clinical trial data presented showed sustained reductions in hyperphagia, as measured by HQ-CT total scores, over multiple years in open-label and controlled studies. The company also emphasized the significant burden PWS places on patients, caregivers, and healthcare systems, including higher rates of hospital stays and increased caregiver stress. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584954619","isCrawlerRequest":true}